key: cord-0990692-a50tctvc
authors: Park, Joung Ha; Cha, Min Jae; Choi, Hyewon; Kim, Min-Chul; Chung, Jin-Won; Lee, Kyu-Sun; Jeong, Dae Gwin; Baek, Moon Seong; Kim, Won-Young; Lim, Yaeji; Yoon, Sun Woo; Choi, Seong-Ho
title: Relationship between SARS-CoV-2 antibody titer and the severity of COVID-19
date: 2022-05-05
journal: J Microbiol Immunol Infect
DOI: 10.1016/j.jmii.2022.04.005
sha: 498a31f2ad454c9b04e7cf3d5d2994604c5a66fe
doc_id: 990692
cord_uid: a50tctvc

Background It remains unclear whether high titers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies aggravate clinical manifestations in patients or whether severe clinical manifestations result in high antibody titers. Thus, we investigated the cause-effect relationship between SARS-CoV-2 antibody titers and disease severity. Methods We prospectively enrolled patients admitted with the diagnosis of coronavirus disease-19 (COVID-19) from February 2020 to August 2020. We measured SARS-CoV-2 antibody titers, namely anti-receptor-binding domain (RBD) antibody and neutralizing antibody (NAb), from blood samples and calculated the chest radiograph (CXR) scores of the patients to evaluate the severity of COVID-19. Results Overall, 40 patients with COVID-19 were enrolled. Pneumonia was observed in more than half of the patients (25/40, 60%). SARS-CoV-2 antibody titers were higher in patients who were aged >60 years (anti-RBD antibodies, P=0.003 and NAb, P=0.009), presented with pneumonia (P=0.006 and 0.007, respectively), and required oxygen therapy (P = 0.003 and 0.004, respectively) than in those who were not. CXR scores peaked (at 15–21 days after the onset of symptoms) statistically significantly earlier than SARS-CoV-2 antibody titers (at 22–30 days for NAb and at 31–70 days for anti-RBD antibody). There was a close correlation between the maximum CXR score and the maximum SAR-CoV-2 antibody titer. Conclusions Based on the comparison of the peak time of SARS-CoV-2 antibody titers with the CXR score after symptom onset, we suggest that severe clinical manifestations result in high titers of SARS-CoV-2 antibodies.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, 27 China at the end of 2019, and the resulting coronavirus disease (COVID-19) pandemic has 28 been threatening the healthcare system worldwide. 1 Therefore, in this study, we aimed to investigate the cause-effect relationship between SARS-47 Study population and study design 52 The study was performed prospectively from February 2020 to August 2020 at Chung-Ang 53 University Hospital in Seoul, South Korea. We prospectively enrolled 40 patients with 54 COVID-19 who were admitted to specially designed isolation rooms with negative pressure 55 and provided consent for the use of their blood samples for detecting SARS-CoV-2 antibody 80 We obtained blood samples of patients to evaluate the changes in total antibody titers to 81 SARS-CoV-2 from the date of admission and throughout their hospitalization periods. We 171 We described the change in antibody titers and CXR scores according to the days after the 

COVID-19-neutralizing antibodies predict disease severity and survival

SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in 334 COVID-19 Convalescent Individuals

Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric 337 live virus micro-neutralization assay in human serum samples

Clinical implication of 340 radiographic scores in acute Middle East respiratory syndrome coronavirus 341 pneumonia: Report from a single tertiary-referral center of South Korea

Cellular and Immunology